The EU has initiated a major overhaul of EU pharma legislation ranging from regulation to intellectual property and supply chains. The off-patent medicines industry is fully engaged to ensure that reforms transform healthcare delivery and access for patients. Generic and biosimilar medicines help the majority of patients with major chronic diseases such as cancer, cardiovascular disease, diabetes, autoimmune conditions and others.
Value added medicines promise affordable, patient-centred innovation which can address unmet medical needs and the crisis in hospitals with personnel shortages and greater demand for healthcare.

Open